First UK patients get Novartis’ Luxturna gene therapy for bl...

More pressure on Bayer as EU approves Novartis' Beovu in wet...

The market for ophthalmology drugs in Europe just got hotter with the approval of Novartis’ Beovu for neovascular or “wet” age-related macular degeneration, offering a less frequent dosing

Novartis plots cardio trial in UK as London HQ opens

Novartis has announced the beginnings of a major cardiovascular outcomes trial in the UK, as it opened a new headquarters in London.

FDA to quickly review Novartis' capmatinib in rare lung canc...

The FDA has agreed to fast-track its regulatory review of Novartis’ capmatinib in a hard-to-treat form of lung cancer.

After rejection, NICE agrees to look again at migraine drug ...

Has pharma been too slow to respond to coronavirus?

The new coronavirus strain emerging in China is making headlines across the world, with the disease sending entire cities into lockdown in a bid to control its spread.